Holen Sie sich die Stockscreener-App
178.63
1.77%
3.42
Icon Plc Aktie (ICLR) Neueste Nachrichten
Icon Plc $ICLR Shares Bought by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
LVM Capital Management Ltd. MI Reduces Holdings in Icon Plc $ICLR - MarketBeat
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $225 - 富途牛牛
Goldman Sachs Group Inc. Sells 106,606 Shares of Icon Plc $ICLR - MarketBeat
17,633 Shares in ICON PLC $ICLR Acquired by Greenhaven Associates Inc. - MarketBeat
Did ICON’s (ICLR) Internal CEO Succession Signal Strategic Continuity or Missed Opportunity for Change? - simplywall.st
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64 - MarketBeat
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy - Insider Monkey
TD Cowen Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $183 - 富途牛牛
Baird Financial Group Inc. Cuts Holdings in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st
Jefferies Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $175 - 富途牛牛
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors - TipRanks
ICON plc’s Latest Study on Kedrion IVIG 10% for Chronic ITP: A Market Perspective - TipRanks
Will ICON’s (ICLR) Leadership Transition Reinforce Operational Continuity or Signal a Strategic Shift? - simplywall.st
Truist Financial Reaffirms Their Buy Rating on Icon (ICLR) - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $220 to $225 - 富途牛牛
ICON plc Reaffirms 2025 Financial Guidance Amid CEO Transition - The Globe and Mail
Icon CEO Steve Cutler to retire, Barry Balfe to succeed - TipRanks
ICON Announces CEO Transition: Dr. Steve Cutler to Retire, Barry Balfe to Take Over - AInvest
ICON plc Announces CEO Changes, Effective October 1, 2025 - MarketScreener
ICON plc Appoints Barry Balfe to the Board - MarketScreener
ICON's Leadership Transition and Market Implications: Succession Strategy and Operational Continuity in Growth-Stage Biotech Firms - AInvest
ICON names Barry Balfe as new CEO effective October 1 By Investing.com - Investing.com Australia
Icon CEO Steve Cutler to Retire; Barry Balfe to Take Reins - MarketScreener
ICON names Barry Balfe as new CEO effective October 1 - Investing.com
ICON Promotes Barry Balfe to CEO Position - AInvest
Icon Promotes COO Barry Balfe to CEO Role - MarketScreener
ICON Announces CEO Transition Effective October 1, 2025 - TipRanks
ICON Announces CEO Transition - FinancialContent
ICON’s Strategic Positioning in the Evolving CRO Landscape - AInvest
ICON plc Announces Participation in September 2025 Investor Conferences - The Globe and Mail
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $224 - 富途牛牛
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
ICON plc to Participate at Upcoming Investor Conferences - PharmiWeb.com
ICON plc to Participate at Upcoming September 2025 Investor Conferences - BioSpace
ICON plc Announces Participation in Upcoming Investor Conferences - AInvest
ICON’s SWOT analysis: stock outlook amid industry headwinds and opportunities - Investing.com
Icon (ICLR) Stock Price, News & Analysis - MarketBeat
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors - Yahoo Finance
Does ICON’s (ICLR) Interim Update Reveal New Clues About Efficiency in Clinical Research Outsourcing? - simplywall.st
ICON plc Releases Interim Financial Statements for 2025 - The Globe and Mail
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):